arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

JOHNSON & JOHNSON

JNJ
$272.34 ▼ -4.00 (-1.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
20 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
76
Health
Good
Bullish
auto_awesome

Analytical Summary

JOHNSON & JOHNSON shows strong fundamentals with top-quartile Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $655.6B
Dividend Yield 1.89%
Revenue Growth 6.0% ↗
Op. Margin None
ROIC None
FCF / Share $8.18 →
Trailing P/E 24.5x
Price / Book —
FCF Yield 3.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

20-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$94.19B
↑ +6.0% —
Net Income Profit after all expenses
$26.80B
↑ +90.6% —
Operating Margin Operating profit as % of sales
29.0%
↑ +26.2% —
FCF / Share Free cash flow per share
$8.18
↓ -0.7% —
Long-Term Debt Long-term obligations
$41.44B
↑ +27.9% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
86
Cash Quality ↓
50

Dividend History

Dividend / share · sourced from SEC filings
$5.14 Latest / share
+4.7% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 76 quarters